Our results could help elucidate the mechanism by which GLP1-RAs exert significant effects on MASLD, indicating potential beneficial effects of semaglutide in the early stages of the metabolic-induced and T2D-associated hepatic injuries (i.e., uncomplicated MASLD). The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.